Longevity Treatment Guides

Hospital HBOT uses hard chambers at UHMS pressures for named indications. Mild soft chambers are not the same treatment. Barotrauma, fire, and oxygen toxicity are real risks.

FDA has not approved ozone to treat diseases. Insufflation and autohemotherapy can cause gas embolism or infection. Inhaled ozone irritates lungs and is not a therapy.

Supervised exercise while breathing oxygen-enriched gas through a mask or cannula. EWOT is not the same as hyperbaric oxygen therapy, and longevity or performance claims exceed current clinical evidence.

A blood-based ozone procedure in which a limited amount of blood is drawn into a sterile container, mixed with a measured oxygen–ozone gas mixture outside the body, then reinfused. It is distinct from EBOO and is not FDA-approved to treat disease.

A screening-first map of ozone therapy, MAH, EBOO, EWOT, and medical hyperbaric oxygen therapy—including major differences in route, pressure, evidence, regulation, and risk.

An invasive, continuous extracorporeal blood procedure in which blood is circulated through a circuit for oxygen–ozone exposure and processing before return. Distinct from limited-volume major autohemotherapy, not FDA-approved to treat disease, and typically cash-pay.

Use of an oxygen–ozone gas mixture by methods such as major autohemotherapy, topical application, or insufflation. Ozone is toxic when inhaled, is not FDA-approved to treat disease in the U.S., and should never be injected directly as gas into a vein.

HBOT involves breathing 100% oxygen in a pressurized chamber, increasing oxygen delivery to tissues. Originally developed for conditions such as decompression sickness, carbon monoxide poisoning, and chronic wounds, it is now also marketed for recovery, wellness, and anti-aging.